Cargando…

Real‐World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma

BACKGROUND: Nivolumab at a dose of 480 mg every 4 weeks (Q4W) is approved for the adjuvant treatment of melanoma. However, real‐world data on this regimen are limited in this setting. METHODS: This retrospective observational study utilized data from the US Oncology Network iKnowMed electronic healt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Samlowski, Wolfram, Robert, Nicholas J., Chen, Liwei, Schenkel, Brad, Davis, Catherine, Moshyk, Andriy, Kotapati, Srividya, Poretta, Tayla, Weber, Jeffrey S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939122/ https://www.ncbi.nlm.nih.gov/pubmed/35880244 http://dx.doi.org/10.1002/cam4.5061

Ejemplares similares

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
por: Potluri, Ravi, et al.
Publicado: (2019)

Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis
por: Toor, Kabirraaj, et al.
Publicado: (2021)

Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067
por: Baker, Timothy, et al.
Publicado: (2022)

Cost–Utility Analysis of Nivolumab in Adjuvant Treatment of Melanoma in France
por: Bregman, Bruno, et al.
Publicado: (2020)

Real-World Recurrence Rates and Economic Burden in Patients with Resected Early-Stage Melanoma
por: Jang, Sekwon, et al.
Publicado: (2020)

Correction to: Real-World Recurrence Rates and Economic Burden in Patients with Resected Early-Stage Melanoma
por: Jang, Sekwon, et al.
Publicado: (2020)

Modelling Survival of Patients Treated with Adjuvant Nivolumab Who Have Melanoma with Lymph Node Involvement or Metastatic Disease After Complete Resection
por: Batteson, Rachael, et al.
Publicado: (2019)

Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
por: Dalle, Stéphane, et al.
Publicado: (2021)

Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival
por: Weber, Jeffrey S., et al.
Publicado: (2022)

Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival
por: Weber, Jeffrey S., et al.
Publicado: (2022)

Outcome of Elective Checkpoint Inhibitor Discontinuation in Patients with Metastatic Melanoma Who Achieved a Complete Remission: Real-World Data
por: Perez, Leanne, et al.
Publicado: (2022)

Real-World Effectiveness, Safety, and Health-Related Quality of Life in Patients Receiving Adjuvant Nivolumab for Melanoma in Belgium and Luxembourg: Results of PRESERV MEL †
por: Rogiers, Anne, et al.
Publicado: (2023)

Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma
por: Federico Paly, Victoria, et al.
Publicado: (2022)

Adherence to Adjuvant Therapy in Patients with Resected Melanoma: An Application of the Theory of Planned Behavior
por: Beisel, Cassie, et al.
Publicado: (2022)

Societal preferences for adjuvant melanoma health states: UK and Australia
por: Middleton, Mark R., et al.
Publicado: (2017)

Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma
por: Asher, Nethanel, et al.
Publicado: (2020)

Retrospective analysis of drug utilization, health care resource use, and costs associated with IFN therapy for adjuvant treatment of malignant melanoma
por: Zhang, Ying, et al.
Publicado: (2015)

A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma(☆)
por: Tarhini, A.A., et al.
Publicado: (2021)

Real‐world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study
por: Middleton, Mark R., et al.
Publicado: (2016)

Management of Melanoma Brain Metastases in the Era of Targeted Therapy
por: Shapiro, Daniela Gonsalves, et al.
Publicado: (2011)

High frequency of brain metastases after adjuvant therapy for high‐risk melanoma
por: Samlowski, Wolfram E., et al.
Publicado: (2017)

Retreatment of Patients With Metastatic Cutaneous Melanoma Who Relapse After Elective Checkpoint Inhibitor Discontinuation After a Complete Remission
por: Sadrolashrafi, Kaviyon, et al.
Publicado: (2023)

Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy
por: Samlowski, Wolfram, et al.
Publicado: (2021)

Unilateral Posterior Uveitis in a Patient Receiving Nivolumab for Malignant Melanoma
por: Giannakis, Periklis, et al.
Publicado: (2023)

Real-World Outcomes and Prognostic Factors in Patients Receiving Nivolumab Therapy for Recurrent or Metastatic Head and Neck Carcinoma
por: Hori, Ryusuke, et al.
Publicado: (2019)

Nivolumab exposure–response analysis for adjuvant treatment of melanoma supporting a change in posology
por: Sanghavi, Kinjal, et al.
Publicado: (2021)

Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment
por: Revicki, Dennis A, et al.
Publicado: (2012)

Real Check RIO: A Real-World Analysis of Nivolumab in First Line Metastatic Melanoma Assessing Efficacy, Safety and Predictive Factors
por: Afrăsânie, Vlad-Adrian, et al.
Publicado: (2023)

Lack of Influence of Non-Overlapping Mutations in BRAF, NRAS, or NF1 on 12-Month Best Objective Response and Long-Term Survival after Checkpoint Inhibitor-Based Treatment for Metastatic Melanoma
por: Panning, Alyssa, et al.
Publicado: (2023)

Is there an Exposure–Response Relationship for Nivolumab in Real-World NSCLC Patients?
por: Bellesoeur, Audrey, et al.
Publicado: (2019)

Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma
por: Chen, Yen-Hao, et al.
Publicado: (2023)

Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival
por: Mandalá, Mario, et al.
Publicado: (2021)

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
por: Weber, Jeffrey S., et al.
Publicado: (2023)

Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab
por: Pasello, Giulia, et al.
Publicado: (2022)

Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma
por: Khushalani, Nikhil I, et al.
Publicado: (2022)

Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience
por: Wu, Wen-Chi, et al.
Publicado: (2022)

Correction to: Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab
Publicado: (2022)

Subset analysis of the safety and efficacy of nivolumab in elderly patients with metastatic melanoma
por: Freeman, Morganna, et al.
Publicado: (2015)

Phase II clinical trial evaluating docetaxel, vinorelbine and GM-CSF in stage IV melanoma
por: Eroglu, Zeynep, et al.
Publicado: (2011)

Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea
por: Lim, Sun Min, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_juq1r4clp4gpqktu862hnb8ldr